{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:34:17Z","timestamp":1789569257481,"version":"build-2803163510"},"reference-count":209,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jconrel.2022.05.002","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T14:25:27Z","timestamp":1652279127000},"page":"211-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Nanomedicine as a magic bullet for combating lymphoma"],"prefix":"10.1016","volume":"347","author":[{"given":"Srushti","family":"Mahajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Aalhate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh Kumar","family":"Guru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.20892\/j.issn.2095-3941.2016.0025","article-title":"Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies","volume":"13","author":"Hocking","year":"2016","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fbioe.2017.00079","article-title":"Nanoparticles\u2014emerging potential for managing leukemia and lymphoma","volume":"5","author":"Vinhas","year":"2017","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"9","key":"10.1016\/j.jconrel.2022.05.002_bb0015","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/adhm.201501007","article-title":"Angiogenesis in liquid Tumors: an in vitro assay for leukemic-cell-induced bone marrow angiogenesis","volume":"5","author":"Zheng","year":"2016","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0020","author":"Rogel Cancer Center University of Michigan Health"},{"issue":"18","key":"10.1016\/j.jconrel.2022.05.002_bb0025","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1101\/gad.284109.116","article-title":"Epigenetics of hematopoiesis and hematological malignancies","volume":"30","author":"Hu","year":"2016","journal-title":"Genes Dev."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0030","series-title":"Concise Guide to Hematology","first-page":"355","article-title":"Classification of lymphomas","author":"McHugh","year":"2019"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0035","series-title":"Hematopoietic and Lymphoid Neoplasm Coding Manual","first-page":"20850","author":"Ruhl","year":"2015"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0040","author":"Cancer treatment centers of America"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0045","article-title":"Trends of non-Hodgkin lymphoma cancer death rates with adjusting the effect of the human development index: the global assessment in 1990\u20132015","volume":"6","author":"Ahmadi","year":"2019","journal-title":"World Cancer Res. J."},{"issue":"20","key":"10.1016\/j.jconrel.2022.05.002_bb0050","first-page":"2375","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"10091","key":"10.1016\/j.jconrel.2022.05.002_bb0055","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.002_bb0060","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.jconrel.2022.05.002_bb0065","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3949\/ccjm.84a.15159","article-title":"Living with hematologic cancer: recommendations, solutions","volume":"84","author":"Faiman","year":"2017","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0070","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2018.08.034","article-title":"Nanomedicines for the treatment of hematological malignancies","volume":"287","author":"Deshantri","year":"2018","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.002_bb0075","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.002_bb0080","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/17474086.2017.1281122","article-title":"Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic\/dendritic cell neoplasms","volume":"10","author":"Jiang","year":"2017","journal-title":"Expert. Rev. Hematol."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0085","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/17474086.2017.1318053","article-title":"Lymphoma classification update: B-cell non-Hodgkin lymphomas","volume":"10","author":"Jiang","year":"2017","journal-title":"Expert. Rev. Hematol."},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0090","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen19X101668","article-title":"Hodgkin lymphoma detection and survival: findings from the haematological malignancy research network","volume":"3","author":"Lamb","year":"2019","journal-title":"BJGP Open"},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0095","first-page":"116","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0100","author":"American cancer society"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0105","series-title":"The Immune Response Basic and Clinical Principles","article-title":"Hematopoietic cancers","author":"Mak","year":"2006"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0110","series-title":"Primary Effusion Lymphoma: A Liquid Phase Lymphoma of Fluid-Filled Body Cavities","author":"Gaidano","year":"2001"},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0115","first-page":"225","article-title":"PEL and HHV8-unrelated effusion lymphomas: classification and diagnosis","volume":"114","author":"Carbone","year":"2008","journal-title":"Cancer Cytopathol. Interdiscip. Int. J. Am. Cancer Soc."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.addr.2017.06.010","article-title":"Drug discovery and therapeutic delivery for the treatment of B and T cell tumors","volume":"114","author":"Stephenson","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"11","key":"10.1016\/j.jconrel.2022.05.002_bb0125","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.3390\/ijms20112832","article-title":"Minimal residual disease monitoring with next-generation sequencing methodologies in hematological malignancies","volume":"20","author":"S\u00e1nchez","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/hon.989","article-title":"Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms","volume":"29","author":"Ferrero","year":"2011","journal-title":"Hematol. Oncol."},{"issue":"22","key":"10.1016\/j.jconrel.2022.05.002_bb0135","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1182\/blood.V128.22.2387.2387","article-title":"Analysis of drugs for hematological malignancy that were granted accelerated approval and feasibility of randomized phase 3 clinical trials for relapsed and refractory hematological malignancy","volume":"128","author":"Nagai","year":"2016","journal-title":"Blood"},{"issue":"S741","key":"10.1016\/j.jconrel.2022.05.002_bb0140","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2796.2001.00689.x","article-title":"Multidrug resistance in haematological malignancies","volume":"249","author":"Sonneveld","year":"2001","journal-title":"J. Intern. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0145","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF03165119","article-title":"Biology and modulation of multidrug resistance (MDR) in hematological malignancies","volume":"76","author":"Hirose","year":"2002","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s10147-016-1045-2","article-title":"T-cell lymphomas, a challenging disease: types, treatments, and future","volume":"22","author":"Ma","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jconrel.2022.05.002_bb0155","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ajh.25513","article-title":"Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management","volume":"94","author":"Zain","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0160","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2005-03-1306","article-title":"T-cell non-Hodgkin lymphoma","volume":"107","author":"Rizvi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0165","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/EDBK_175437","article-title":"Understanding the new WHO classification of lymphoid malignancies: why it's important and how it will affect practice","volume":"37","author":"Jaffe","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educat. Book"},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0170","article-title":"Aggressive B-cell lymphomas\u2014from morphology to molecular pathogenesis","volume":"3","author":"Chen","year":"2019","journal-title":"Ann. Lymphoma"},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.beha.2018.04.001","article-title":"CAR T cell therapy for B-cell lymphomas","volume":"31","author":"Chavez","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0180","author":"American cancer society"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0185","series-title":"Mayo Clinic Proceedings","article-title":"Non-Hodgkin lymphoma: Diagnosis and treatment","author":"Ansell","year":"2015"},{"issue":"12","key":"10.1016\/j.jconrel.2022.05.002_bb0190","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/ajh.24936","article-title":"Hairy cell leukemia 2018: update on diagnosis, risk-stratification, and treatment","volume":"92","author":"Troussard","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0195","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.anndiagpath.2018.09.014","article-title":"Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues","volume":"38","author":"Grimm","year":"2019","journal-title":"Ann. Diagn. Pathol."},{"issue":"18","key":"10.1016\/j.jconrel.2022.05.002_bb0200","first-page":"1879","article-title":"Biology and management of primary effusion lymphoma","volume":"132","author":"Shimada","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"9","key":"10.1016\/j.jconrel.2022.05.002_bb0205","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.bcp.2013.02.017","article-title":"Molecular aspects of cancer cell resistance to chemotherapy","volume":"85","author":"Rebucci","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0210","first-page":"1","article-title":"Histopathological study of the hepatic and renal toxicity associated with the co-administration of imatinib and acetaminophen in a preclinical mouse model","volume":"32","author":"Nassar","year":"2010","journal-title":"Malays. J. Pathol."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0215","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ejmech.2006.01.013","article-title":"Prediction of human absorption of natural compounds by the non-everted rat intestinal sac model","volume":"41","author":"Ruan","year":"2006","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0220","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejps.2015.08.002","article-title":"Simultaneous improvement of solubility and permeability by fabricating binary glassy materials of Talinolol with Naringin: solid state characterization, in-vivo in-situ evaluation","volume":"78","author":"Teja","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"issue":"25","key":"10.1016\/j.jconrel.2022.05.002_bb0225","first-page":"2639","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0230","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd3629","article-title":"Brentuximab vedotin","volume":"11","author":"Younes","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0235","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0240","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0245","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-1-4939-6872-5_15","article-title":"Overview of targeted therapies for adult T-cell leukemia\/lymphoma","author":"Nasr","year":"2017","journal-title":"Human T-Lymphotropic Viruses"},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0250","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/2040620715592567","article-title":"Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review","volume":"6","author":"Sawas","year":"2015","journal-title":"Therap. Adv. Hematol."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2018.03.002","article-title":"Next-generation proteasome inhibitors for cancer therapy","volume":"198","author":"Park","year":"2018","journal-title":"Transl. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0260","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","article-title":"Bortezomib for the treatment of hematologic malignancies: 15 years later","volume":"19","author":"Robak","year":"2019","journal-title":"Drugs R & D"},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0265","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3747\/co.26.4345","article-title":"Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma","volume":"26","author":"Owen","year":"2019","journal-title":"Curr. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2022.05.002_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-020-00746-8","article-title":"PI3K inhibitors and their role as novel agents for targeted therapy in lymphoma","volume":"21","author":"Sapon-Cousineau","year":"2020","journal-title":"Curr. Treat. Options in Oncol."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0275","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.jconrel.2022.05.002_bb0280","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol."},{"issue":"5\u20136","key":"10.1016\/j.jconrel.2022.05.002_bb0285","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/02841860310013346","article-title":"A systematic overview of radiation therapy effects in Hodgkin\u2019s lymphoma","volume":"42","author":"Gustavsson","year":"2003","journal-title":"Acta Oncol."},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0290","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5\u20136","key":"10.1016\/j.jconrel.2022.05.002_bb0295","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/02841860310014435","article-title":"A systematic overview of radiation therapy effects in non-Hodgkin\u2019s lymphoma","volume":"42","author":"Gustavsson","year":"2003","journal-title":"Acta Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0300","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-Hodgkin lymphoma\u2014target definition and dose guidelines from the international lymphoma radiation oncology group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0305","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.adro.2020.06.001","article-title":"Radiation therapy for advanced-stage Hodgkin lymphoma","volume":"5","author":"Lockney","year":"2020","journal-title":"Adv. Radiat. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.002_bb0310","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother. Oncol."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0315","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved site radiation therapy in adult lymphomas: an overview of international lymphoma radiation oncology group guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0320","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0325","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.path.2015.10.001","article-title":"Lymphoma microenvironment and immunotherapy","volume":"9","author":"Xu","year":"2016","journal-title":"Surg. Pathol. Clin."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0330","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0335","series-title":"Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL)","author":"Reyes","year":"2014"},{"issue":"6","key":"10.1016\/j.jconrel.2022.05.002_bb0340","first-page":"1793","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004"},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0345","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3324\/haematol.2015.124107","article-title":"Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia","volume":"100","author":"Sandhu","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0350","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.critrevonc.2016.07.008","article-title":"Zevalin\u00ae(ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned?","volume":"105","author":"Rizzieri","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"7","key":"10.1016\/j.jconrel.2022.05.002_bb0355","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0360","first-page":"1","article-title":"Loncastuximab tesirine: first approval","author":"Lee","year":"2021","journal-title":"Drugs"},{"issue":"35","key":"10.1016\/j.jconrel.2022.05.002_bb0365","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0370","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0375","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1517\/13543784.2015.1021415","article-title":"Blinatumomab for the treatment of B-cell lymphoma","volume":"24","author":"Oak","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"6","key":"10.1016\/j.jconrel.2022.05.002_bb0380","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41578-019-0108-1","article-title":"Cancer nanomedicine for combination cancer immunotherapy","volume":"4","author":"Nam","year":"2019","journal-title":"Nat. Rev. Mater."},{"issue":"11","key":"10.1016\/j.jconrel.2022.05.002_bb0385","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14712598.2020.1830056","article-title":"Pembrolizumab for the treatment of Hodgkin lymphoma","volume":"20","author":"Al Hadidi","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2022.05.002_bb0390","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12272-019-01136-x","article-title":"Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives","volume":"42","author":"Lee","year":"2019","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0395","series-title":"A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed\/Refractory Aggressive B-Cell Lymphomas","author":"Riedell","year":"2019"},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0400","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CJI.0000000000000307","article-title":"Antitumor potency of an anti-CD19 chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib","volume":"43","author":"Qin","year":"2020","journal-title":"J. Immunother."},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0405","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14712598.2021.1889510","article-title":"Brexucabtagene autoleucel for the treatment of relapsed\/refractory mantle cell lymphoma","volume":"21","author":"Mian","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0410","doi-asserted-by":"crossref","first-page":"128","DOI":"10.6004\/jnccn.2014.0010","article-title":"Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic","volume":"12","author":"Wildes","year":"2014","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"20","key":"10.1016\/j.jconrel.2022.05.002_bb0415","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2003.08.054","volume":"21","author":"Bierman","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.002_bb0420","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","article-title":"A review of autologous stem cell transplantation in lymphoma","volume":"12","author":"Zahid","year":"2017","journal-title":"Curr. Hematol. Malignancy Rep."},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0425","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/annonc\/mdn691","article-title":"Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up","volume":"20","author":"Kornacker","year":"2009","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.002_bb0430","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/cells9030563","article-title":"Recent progress of stem cell therapy in cancer treatment: molecular mechanisms and potential applications","volume":"9","author":"Chu","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0435","unstructured":"Targeting the Tumor Microenvironment May Be a Key Development in Follicular Lymphoma Treatment. [cited 20-04-2022; Available from: https:\/\/www.celgene.com\/follicular-lymphoma\/."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0440","series-title":"Seminars in Cancer Biology","article-title":"Cancer prevention and therapy through the modulation of the tumor microenvironment","author":"Casey","year":"2015"},{"issue":"21","key":"10.1016\/j.jconrel.2022.05.002_bb0445","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.3390\/ijms20215503","article-title":"Immune and inflammatory cells of the tumor microenvironment represent novel therapeutic targets in classical Hodgkin lymphoma","volume":"20","author":"Calabretta","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0450","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Disc."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0455","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/sj.leu.2404970","article-title":"Lymphoma microenvironment: culprit or innocent?","volume":"22","author":"Herreros","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jconrel.2022.05.002_bb0460","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1002\/cam4.2327","article-title":"Crosstalk between cancer and immune cells: role of tumor-associated macrophages in the tumor microenvironment","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01134-x","article-title":"Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"18","key":"10.1016\/j.jconrel.2022.05.002_bb0470","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0797-3","article-title":"Myeloid-derived suppressor cells in hematological malignancies: friends or foes","volume":"12","author":"Lv","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"7629","key":"10.1016\/j.jconrel.2022.05.002_bb0480","first-page":"443","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"49","key":"10.1016\/j.jconrel.2022.05.002_bb0485","doi-asserted-by":"crossref","first-page":"E10578","DOI":"10.1073\/pnas.1710877114","article-title":"Anti-SIRP\u03b1 antibody immunotherapy enhances neutrophil and macrophage antitumor activity","volume":"114","author":"Ring","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105010","article-title":"CXCR4 antagonist AMD3100 (plerixafor): from an impurity to a therapeutic agent","volume":"159","author":"Wang","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.jconrel.2022.05.002_bb0495","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.trecan.2019.05.001","article-title":"Targeting the tumor microenvironment of leukemia and lymphoma","volume":"5","author":"H\u00f6pken","year":"2019","journal-title":"Trends Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0500","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.jconrel.2022.05.002_bb0505","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.3390\/cells9102287","article-title":"Targeting DNA repair, cell cycle, and tumor microenvironment in B cell lymphoma","volume":"9","author":"Br\u00f6ckelmann","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.jconrel.2022.05.002_bb0510","first-page":"518","article-title":"Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy","volume":"13","author":"Montanari","year":"2015"},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0515","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2217\/nnm.12.22","article-title":"Cancer stem cells and drug resistance: the potential of nanomedicine","volume":"7","author":"Vinogradov","year":"2012","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.002_bb0520","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.drup.2011.01.003","article-title":"Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance","volume":"14","author":"Shapira","year":"2011","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0525","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2014.05.036","article-title":"State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines","volume":"187","author":"Dawidczyk","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0530","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jconrel.2019.01.011","article-title":"Combinatorial nanocarriers against drug resistance in hematological cancers: opportunities and emerging strategies","volume":"296","author":"Ghosh","year":"2019","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.002_bb0535","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0540","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.critrevonc.2006.11.006","article-title":"Angiogenesis and antiangiogenic therapy in hematologic malignancies","volume":"62","author":"Dong","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.002_bb0545","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1040-8428(02)00135-X","article-title":"Angiogenesis in hematologic malignancies","volume":"45","author":"Moehler","year":"2003","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"12","key":"10.1016\/j.jconrel.2022.05.002_bb0550","first-page":"3712","article-title":"Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients","volume":"96","author":"Salven","year":"2000","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"10","key":"10.1016\/j.jconrel.2022.05.002_bb0555","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/sj.leu.2404350","article-title":"Jak3-and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma","volume":"20","author":"Krejsgaard","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0560","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/01674820500305838","article-title":"Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL)","volume":"47","author":"Mainou-Fowler","year":"2006","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0565","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jconrel.2011.07.018","article-title":"PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma","volume":"155","author":"Xiao","year":"2011","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.002_bb0570","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3324\/haematol.2018.211490","article-title":"A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models","volume":"105","author":"Falg\u00e0s","year":"2020","journal-title":"haematologica"},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0575","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjh.12446","volume":"162","author":"Hagemeister","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0580","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clml.2013.09.009","article-title":"Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-cell lymphoma or mantle cell lymphoma in need of palliative therapy","volume":"14","author":"Kaplan","year":"2014","journal-title":"Clin. Lymph. Myeloma Leukemia"},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0590","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1080\/10428190802007700","article-title":"A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma","volume":"49","author":"Mitchell","year":"2008","journal-title":"Leuk. Lymphoma"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2022.05.002_bb0595","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijpharm.2016.02.019","article-title":"Lipid-based nanoformulations for peptide delivery","volume":"502","author":"Matougui","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0600","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2017.04.006","article-title":"Dual-functional drug liposomes in treatment of resistant cancers","volume":"115","author":"Mu","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0605","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejpb.2018.10.017","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release","volume":"133","author":"Gordillo-Galeano","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0610","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.2147\/IJN.S133034","article-title":"Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma","volume":"12","author":"Alekseeva","year":"2017","journal-title":"Int. J. Nanomedicine"},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0615","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/btm2.10088","article-title":"Lipid nanoparticle siRNA cocktails for the treatment of mantle cell lymphoma","volume":"3","author":"Knapp","year":"2018","journal-title":"Bioeng. Trans. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0620","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.3109\/10717544.2015.1041580","article-title":"Targeted delivery of doxorubicin and vincristine to lymph cancer: evaluation of novel nanostructured lipid carriers in vitro and in vivo","volume":"23","author":"Dong","year":"2016","journal-title":"Drug Deliv."},{"issue":"9","key":"10.1016\/j.jconrel.2022.05.002_bb0625","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.molmed.2015.06.005","article-title":"Cell-penetrating peptides: strategies for anticancer treatment","volume":"21","author":"Raucher","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0630","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.biopha.2017.04.104","article-title":"Transcription activator, hyaluronic acid and tocopheryl succinate multi-functionalized novel lipid carriers encapsulating etoposide for lymphoma therapy","volume":"91","author":"Wang","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0635","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-017-0652-8","article-title":"Smoldering mantle cell lymphoma","volume":"36","author":"Ye","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0645","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1073\/pnas.1519273113","article-title":"Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies","volume":"113","author":"Weinstein","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0650","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.nano.2015.02.022","article-title":"Folic acid-tagged protein nanoemulsions loaded with CORM-2 enhance the survival of mice bearing subcutaneous A20 lymphoma tumors","volume":"11","author":"Loureiro","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0655","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2147\/DDDT.S152420","article-title":"Lymphoma-targeted treatment using a folic acid-decorated vincristine-loaded drug delivery system","volume":"12","author":"Qiu","year":"2018","journal-title":"Drug Design Dev. Therapy"},{"issue":"9","key":"10.1016\/j.jconrel.2022.05.002_bb0660","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1158\/1078-0432.CCR-04-2517","article-title":"Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates","volume":"11","author":"Allen","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.jconrel.2022.05.002_bb0665","first-page":"4778","article-title":"In vivo targeting of B-cell lymphoma with glycan ligands of CD22","volume":"115","author":"Chen","year":"2010","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"7","key":"10.1016\/j.jconrel.2022.05.002_bb0670","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1158\/1078-0432.CCR-03-0376","article-title":"Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes","volume":"10","author":"Sapra","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0675","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.canlet.2008.04.024","article-title":"Tumor targeting of vincristine by mBAFF-modified PEG liposomes in B lymphoma cells","volume":"269","author":"Zhang","year":"2008","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0680","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jconrel.2003.09.016","article-title":"Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells","volume":"94","author":"Lundberg","year":"2004","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0685","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1078-0432.CCR-12-2046","article-title":"Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies","volume":"19","author":"Mao","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0690","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.yexmp.2010.01.006","article-title":"Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv","volume":"88","author":"Loomis","year":"2010","journal-title":"Exp. Mol. Pathol."},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0695","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/1535-7163.MCT-05-0543","article-title":"Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors","volume":"5","author":"Shmeeda","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"34","key":"10.1016\/j.jconrel.2022.05.002_bb0700","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1016\/j.biomaterials.2013.07.068","article-title":"Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma","volume":"34","author":"Molavi","year":"2013","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0705","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejps.2010.06.012","article-title":"Cidofovir-loaded liposomes: an intro-study using BCBL-1 cell line as a model for primary effusion lymphoma","volume":"41","author":"Ruozi","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"issue":"291","key":"10.1016\/j.jconrel.2022.05.002_bb0710","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa5447","article-title":"Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells","volume":"7","author":"Huang","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2022.05.002_bb0715","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/1535370216640944","article-title":"Lipidoid nanoparticle mediated silencing of mcl-1 induces apoptosis in mantle cell lymphoma","volume":"241","author":"Knapp","year":"2016","journal-title":"Exp. Biol. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0720","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2217\/nnm.11.134","article-title":"Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles","volume":"7","author":"Estella-Hermoso de Mendoza","year":"2012","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0725","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/08982104.2020.1720718","article-title":"Co-delivery of rituximab targeted curcumin and imatinib nanostructured lipid carriers in non-Hodgkin lymphoma cells","volume":"31","author":"Varshosaz","year":"2021","journal-title":"J. Liposome Res."},{"issue":"9","key":"10.1016\/j.jconrel.2022.05.002_bb0730","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2217\/nnm.11.50","article-title":"Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity","volume":"6","author":"Popov","year":"2011","journal-title":"Nanomedicine"},{"issue":"11","key":"10.1016\/j.jconrel.2022.05.002_bb0735","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2015.126854","article-title":"Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1\/PRDM1 in primary effusion lymphoma","volume":"100","author":"Riva","year":"2015","journal-title":"Haematologica"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2022.05.002_bb0740","first-page":"675","article-title":"Polymeric nanoparticles: promising platform for drug delivery","volume":"528","author":"Khalid","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.002_bb0745","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11705-016-1582-2","article-title":"Polymeric micelle nanocarriers in cancer research","volume":"10","author":"Shin","year":"2016","journal-title":"Front. Chem. Sci. Eng."},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0750","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/molecules23040938","article-title":"Dendrimers for drug delivery","volume":"23","author":"Chauhan","year":"2018","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0755","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41573-018-0005-0","article-title":"Polymer\u2013drug conjugate therapeutics: advances, insights and prospects","volume":"18","author":"Ekladious","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0760","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ijpharm.2019.04.013","article-title":"CD30 aptamer-functionalized PEG-PLGA nanoparticles for the superior delivery of doxorubicin to anaplastic large cell lymphoma cells","volume":"564","author":"Luo","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0765","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.2005.03.8471","article-title":"Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy","volume":"24","author":"Goldenberg","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.jconrel.2022.05.002_bb0770","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1039\/C5CS00784D","article-title":"New insights into the pretargeting approach to image and treat tumours","volume":"45","author":"Patra","year":"2016","journal-title":"Chem. Soc. Rev."},{"issue":"14","key":"10.1016\/j.jconrel.2022.05.002_bb0775","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz9798","article-title":"Pretargeted delivery of PI3K\/mTOR small-molecule inhibitor\u2013loaded nanoparticles for treatment of non-Hodgkin\u2019s lymphoma","volume":"6","author":"Au","year":"2020","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0780","first-page":"1392","article-title":"Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin","volume":"97","author":"Ghetie","year":"2001","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"8","key":"10.1016\/j.jconrel.2022.05.002_bb0785","doi-asserted-by":"crossref","first-page":"834","DOI":"10.7150\/thno.12040","article-title":"A two-step pretargeted nanotherapy for CD20 crosslinking may achieve superior anti-lymphoma efficacy to rituximab","volume":"5","author":"Chu","year":"2015","journal-title":"Theranostics"},{"issue":"20","key":"10.1016\/j.jconrel.2022.05.002_bb0790","doi-asserted-by":"crossref","first-page":"1900018","DOI":"10.1002\/adfm.201900018","article-title":"Binary targeting of siRNA to hematologic cancer cells in vivo using layer-by-layer nanoparticles","volume":"29","author":"Choi","year":"2019","journal-title":"Adv. Funct. Mater."},{"issue":"9","key":"10.1016\/j.jconrel.2022.05.002_bb0795","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41551-019-0434-z","article-title":"Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice","volume":"3","author":"Wen","year":"2019","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0800","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00505-8","article-title":"Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers","volume":"8","author":"Moffett","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep45682","article-title":"Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma","volume":"7","author":"Nevala","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.jconrel.2022.05.002_bb0810","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/1061186X.2014.897708","article-title":"Preparation of vincristine sulfate-loaded poly (butylcyanoacrylate) nanoparticles modified with pluronic F127 and evaluation of their lymphatic tissue targeting","volume":"22","author":"Tan","year":"2014","journal-title":"J. Drug Target."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2022.05.002_bb0815","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijpharm.2015.05.029","article-title":"Nutlin-3 loaded nanocarriers: preparation, characterization and in vitro antineoplastic effect against primary effusion lymphoma","volume":"490","author":"Belletti","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0820","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.actbio.2020.11.014","article-title":"Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma","volume":"119","author":"Pola","year":"2021","journal-title":"Acta Biomater."},{"issue":"sup2","key":"10.1016\/j.jconrel.2022.05.002_bb0825","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/21691401.2018.1478844","article-title":"Rituximab (anti-CD20)-modified AZD-2014-encapsulated nanoparticles killing of B lymphoma cells","volume":"46","author":"Tang","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0830","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1039\/C9BM01750J","article-title":"Angiopep-2 conjugated nanoparticles loaded with doxorubicin for the treatment of primary central nervous system lymphoma","volume":"8","author":"Shi","year":"2020","journal-title":"Biomater. Sci."},{"issue":"11","key":"10.1016\/j.jconrel.2022.05.002_bb0835","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1021\/acs.molpharmaceut.7b00606","article-title":"Lymphoma immunochemotherapy: targeted delivery of doxorubicin via a dual functional nanocarrier","volume":"14","author":"Zhai","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0840","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jconrel.2020.08.042","article-title":"Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab","volume":"328","author":"Lidick\u00fd","year":"2020","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0845","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acsnano.7b08122","article-title":"Bespoke pretargeted nanoradioimmunotherapy for the treatment of non-Hodgkin lymphoma","volume":"12","author":"Au","year":"2018","journal-title":"ACS Nano"},{"issue":"26","key":"10.1016\/j.jconrel.2022.05.002_bb0850","doi-asserted-by":"crossref","first-page":"E1695","DOI":"10.1073\/pnas.1201516109","article-title":"Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma","volume":"109","author":"Babar","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.jconrel.2022.05.002_bb0855","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1039\/c2tb00301e","article-title":"Individual inorganic nanoparticles: preparation, functionalization and in vitro biomedical diagnostic applications","volume":"1","author":"Ladj","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0860","series-title":"NanoScience in Biomedicine","first-page":"272","article-title":"Inorganic nanoparticles for biomedical applications","author":"Tan","year":"2009"},{"issue":"10","key":"10.1016\/j.jconrel.2022.05.002_bb0865","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1039\/c0nr00161a","article-title":"Water soluble nanoporous nanoparticle for in vivo targeted drug delivery and controlled release in B cells tumor context","volume":"2","author":"De Angelis","year":"2010","journal-title":"Nanoscale"},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0870","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11596-017-1783-z","article-title":"Carbon nanotubes-based drug delivery to cancer and brain","volume":"37","author":"Guo","year":"2017","journal-title":"Curr. Med. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.002_bb0875","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.nano.2008.04.003","article-title":"Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues","volume":"4","author":"Foldvari","year":"2008","journal-title":"Nanomedicine"},{"issue":"Supplement 1","key":"10.1016\/j.jconrel.2022.05.002_bb0880","first-page":"1476","article-title":"Targeting Burkitt\u2019s lymphoma using novel, discrete carbon nanotubes","volume":"130","author":"Falank","year":"2017","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"10","key":"10.1016\/j.jconrel.2022.05.002_bb0885","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nnano.2013.190","article-title":"Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery","volume":"8","author":"Mulvey","year":"2013","journal-title":"Nat. Nanotechnol."},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.002_bb0890","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058491","article-title":"Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo","volume":"8","author":"Ahn","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0895","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-021-00922-4","article-title":"Biomimetic nanotherapy: core\u2013shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma","volume":"19","author":"Zhao","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0900","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1021\/acsnano.9b06333","article-title":"Specific inhibition of viral MicroRNAs by carbon dots-mediated delivery of locked nucleic acids for therapy of virus-induced cancer","volume":"14","author":"Ju","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0905","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.2147\/IJN.S118661","article-title":"Nanoparticle-based strategy for personalized B-cell lymphoma therapy","volume":"11","author":"Martucci","year":"2016","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-020-00738-8","article-title":"Construction of homologous cancer cell membrane camouflage in a nano-drug delivery system for the treatment of lymphoma","volume":"19","author":"Zhao","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb0915","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/adfm.201403822","article-title":"Gated mesoporous silica nanoparticles using a double-role circular peptide for the controlled and target-preferential release of doxorubicin in CXCR4-expresing lymphoma cells","volume":"25","author":"De La Torre","year":"2015","journal-title":"Adv. Funct. Mater."},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.002_bb0920","doi-asserted-by":"crossref","first-page":"1900446","DOI":"10.1002\/ppsc.201900446","article-title":"Selective targeting of lymphoma cells by monoclonal antibody grafted onto zwitterionic-functionalized nanoparticles","volume":"37","author":"de Oliveira","year":"2020","journal-title":"Part. Part. Syst. Charact."},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb0925","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/pharmaceutics10040283","article-title":"Enhanced solubility, permeability and anticancer activity of vorinostat using tailored mesoporous silica nanoparticles","volume":"10","author":"Meka","year":"2018","journal-title":"Pharmaceutics"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2022.05.002_bb0930","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.wneu.2013.01.011","article-title":"Targeted cell uptake of a noninternalizing antibody through conjugation to iron oxide nanoparticles in primary central nervous system lymphoma","volume":"80","author":"Wang","year":"2013","journal-title":"World Neurosurg."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0935","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/IJN.S185458","article-title":"Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression","volume":"14","author":"Song","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0940","doi-asserted-by":"crossref","first-page":"102290","DOI":"10.1016\/j.nano.2020.102290","article-title":"Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma","volume":"30","author":"Lin","year":"2020","journal-title":"Nanomedicine"},{"issue":"11","key":"10.1016\/j.jconrel.2022.05.002_bb0945","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1021\/acs.molpharmaceut.7b00710","article-title":"Rational targeting of cellular cholesterol in diffuse large B-cell lymphoma (DLBCL) enabled by functional lipoprotein nanoparticles: a therapeutic strategy dependent on cell of origin","volume":"14","author":"Rink","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0950","doi-asserted-by":"crossref","first-page":"111648","DOI":"10.1016\/j.msec.2020.111648","article-title":"Construction of biomimetic silver nanoparticles in the treatment of lymphoma","volume":"119","author":"Zhao","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0955","doi-asserted-by":"crossref","first-page":"102025","DOI":"10.1016\/j.nano.2019.102025","article-title":"Development of medical-grade, discrete, multi-walled carbon nanotubes as drug delivery molecules to enhance the treatment of hematological malignancies","volume":"20","author":"Falank","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0960","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jconrel.2014.05.002","article-title":"Stimuli-sensitive nanopreparations for combination cancer therapy","volume":"190","author":"Jhaveri","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.05.002_bb0965","doi-asserted-by":"crossref","first-page":"103375","DOI":"10.1016\/j.bioorg.2019.103375","article-title":"Preparation and anti-Raji lymphoma efficacy of a novel pH sensitive and magnetic targeting nanoparticles drug delivery system","volume":"94","author":"Cai","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1556-276X-9-447","article-title":"Potentiating antilymphoma efficacy of chemotherapy using a liposome for integration of CD20 targeting, ultra-violet irradiation polymerizing, and controlled drug delivery","volume":"9","author":"Wu","year":"2014","journal-title":"Nanoscale Res. Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb0975","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-017-0492-6","article-title":"Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells","volume":"36","author":"Zhou","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0980","first-page":"2220","article-title":"Tissue factor-targeted \u201cO2-evolving\u201d nanoparticles for photodynamic therapy in malignant lymphoma","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2022.05.002_bb0985","doi-asserted-by":"crossref","first-page":"9647","DOI":"10.2147\/IJN.S205456","article-title":"Preparation and characterization of Fe3O4@ MTX magnetic nanoparticles for thermochemotherapy of primary central nervous system lymphoma in vitro and in vivo","volume":"14","author":"Dai","year":"2019","journal-title":"Int. J. Nanomedicine"},{"issue":"18","key":"10.1016\/j.jconrel.2022.05.002_bb0990","doi-asserted-by":"crossref","first-page":"8250","DOI":"10.7150\/thno.45803","article-title":"pH-responsive DNA nanomicelles for chemo-gene synergetic therapy of anaplastic large cell lymphoma","volume":"10","author":"Li","year":"2020","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.jconrel.2022.05.002_bb0995","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jconrel.2012.06.030","article-title":"Controlled release of rituximab from gold nanoparticles for phototherapy of malignant cells","volume":"162","author":"Bisker","year":"2012","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2022.05.002_bb1000","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/cbdd.12551","article-title":"Controlled and targeted drug delivery by a UV-responsive liposome for overcoming chemo-resistance in non-Hodgkin lymphoma","volume":"86","author":"Li","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"issue":"6","key":"10.1016\/j.jconrel.2022.05.002_bb1005","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1021\/mp300128b","article-title":"Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma","volume":"9","author":"Kato","year":"2012","journal-title":"Mol. Pharm."},{"issue":"01","key":"10.1016\/j.jconrel.2022.05.002_bb1010","doi-asserted-by":"crossref","first-page":"1950013","DOI":"10.1142\/S1793292019500139","article-title":"Doxorubicin-loaded CuS nanoparticles conjugated with GFLG: a novel drug delivery system for lymphoma treatment","volume":"14","author":"Jiang","year":"2019","journal-title":"NANO: Brief Rep. Rev."},{"issue":"7","key":"10.1016\/j.jconrel.2022.05.002_bb1015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/natrevmats.2017.24","article-title":"Rethinking cancer nanotheranostics","volume":"2","author":"Chen","year":"2017","journal-title":"Nat. Rev. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.002_bb1020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/ntno.17109","article-title":"Remotely triggered nano-theranostics for cancer applications","volume":"1","author":"Sneider","year":"2017","journal-title":"Nanotheranostics"},{"key":"10.1016\/j.jconrel.2022.05.002_bb1025","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2018.09.018","article-title":"Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging","volume":"289","author":"Etrych","year":"2018","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.jconrel.2022.05.002_bb1030","doi-asserted-by":"crossref","first-page":"10301","DOI":"10.1021\/acsnano.9b03727","article-title":"Biomimetic magnetic nanostructures: a theranostic platform targeting lipid metabolism and immune response in lymphoma","volume":"13","author":"Singh","year":"2019","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.jconrel.2022.05.002_bb1035","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1039\/C9TB02521A","article-title":"Rituximab conjugated iron oxide nanoparticles for targeted imaging and enhanced treatment against CD20-positive lymphoma","volume":"8","author":"Song","year":"2020","journal-title":"J. Mater. Chem. B"},{"issue":"26","key":"10.1016\/j.jconrel.2022.05.002_bb1040","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1039\/C7TB00152E","article-title":"Rituxan nanoconjugation prolongs drug\/cell interaction and enables simultaneous depletion and enhanced Raman detection of lymphoma cells","volume":"5","author":"Yao","year":"2017","journal-title":"J. Mater. Chem. B"},{"issue":"35","key":"10.1016\/j.jconrel.2022.05.002_bb1045","doi-asserted-by":"crossref","first-page":"18418","DOI":"10.1039\/D0NR04450D","article-title":"Modular design of bi-specific nanoplatform engaged in malignant lymphoma immunotherapy","volume":"12","author":"Bai","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2022.05.002_bb1050","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.colsurfb.2017.11.003","article-title":"Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma","volume":"161","author":"Saesoo","year":"2018","journal-title":"Colloids Surf. B: Biointerfaces"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922002589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922002589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:19:25Z","timestamp":1759162765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922002589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":209,"alternative-id":["S0168365922002589"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.05.002","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanomedicine as a magic bullet for combating lymphoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}